Your browser is no longer supported. Please, upgrade your browser.
Settings
HEPA [NASD]
Hepion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.78 Insider Own0.20% Shs Outstand9.03M Perf Week3.60%
Market Cap69.00M Forward P/E- EPS next Y-1.09 Insider Trans114.17% Shs Float7.88M Perf Month27.78%
Income-17.30M PEG- EPS next Q-0.39 Inst Own17.50% Short Float2.58% Perf Quarter-34.47%
Sales- P/S- EPS this Y93.70% Inst Trans- Short Ratio0.10 Perf Half Y-37.84%
Book/sh1.24 P/B1.85 EPS next Y27.80% ROA-78.50% Target Price- Perf Year-58.48%
Cash/sh0.46 P/C5.04 EPS next 5Y- ROE-116.80% 52W Range1.00 - 6.90 Perf YTD5.02%
Dividend- P/FCF- EPS past 5Y59.90% ROI- 52W High-66.67% Beta1.34
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low130.00% ATR0.19
Employees12 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)56.58 Volatility7.03% 8.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-30.50% Profit Margin- Rel Volume0.54 Prev Close2.34
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume1.99M Price2.30
Recom2.00 SMA207.48% SMA504.28% SMA200-14.06% Volume1,069,953 Change-1.71%
Jul-20-20Resumed ROTH Capital Buy $14
Jan-05-21 08:00AM  
Dec-29-20 04:15PM  
07:30AM  
Dec-22-20 07:30AM  
Dec-10-20 08:55AM  
Dec-02-20 07:30AM  
Nov-30-20 05:30PM  
12:44PM  
Nov-24-20 07:20PM  
Nov-18-20 07:30AM  
Nov-17-20 04:30PM  
Nov-12-20 08:30AM  
Nov-10-20 09:00AM  
Nov-05-20 08:57AM  
Oct-27-20 07:45AM  
Oct-05-20 07:30AM  
Sep-29-20 08:30AM  
Sep-17-20 08:00AM  
Sep-01-20 07:30AM  
Aug-27-20 07:15AM  
Aug-12-20 07:15AM  
Aug-05-20 07:15AM  
Jul-07-20 07:30AM  
Jun-29-20 04:15PM  
Jun-22-20 04:15PM  
Jun-10-20 04:15PM  
May-20-20 04:15PM  
May-19-20 07:00AM  
Mar-12-20 08:15AM  
Feb-19-20 04:30PM  
Feb-12-20 04:15PM  
Jan-28-20 04:15PM  
Jan-08-20 04:15PM  
Jan-06-20 04:15PM  
Dec-23-19 11:17AM  
Dec-12-19 11:42AM  
Dec-11-19 09:08AM  
Dec-10-19 04:20PM  
Dec-09-19 04:15PM  
Dec-03-19 04:15PM  
08:30AM  
Nov-21-19 09:01AM  
08:04AM  
Nov-20-19 04:15PM  
Nov-07-19 04:15PM  
08:30AM  
Oct-23-19 04:15PM  
Oct-16-19 04:15PM  
Oct-10-19 08:00AM  
Oct-03-19 04:15PM  
Sep-04-19 08:30AM  
Sep-03-19 04:30PM  
Aug-14-19 08:30AM  
Aug-07-19 01:00PM  
Jul-31-19 09:20AM  
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorDec 18Buy1.9120,00038,20020,000Dec 21 09:17 AM
Foster Robert TCEO and DirectorDec 08Buy1.5825,00039,41825,259Dec 08 01:56 PM
BRANCACCIO JOHN PDirectorDec 02Buy1.537,00010,7107,008Dec 02 06:05 PM
JACOB GARY SDirectorDec 01Buy1.6612,00019,92012,059Dec 01 07:53 PM
Cavan John TChief Financial OfficerNov 25Buy1.624,5007,2904,800Nov 30 04:53 PM